Ketamine Treatment

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of proprietary R-ketamine, PCN-101. Open-label, the trial is set to assess...

PharmaTher Holdings Ltd. (OTCQB: PHRRF)’s recent meeting with the FDA on the feasibility of a Phase 3 program for proprietary ketamine KETARX to treat levodopa-induced dyskinesia in Parkinson’s disease (LID-PD) was successful, considering the federal agency supported the company’s...

Biopharma company Silo Pharma Inc. (NASDAQ: SILO) filed a provisional patent application to the US Patent and Trading Office covering “methods and compositions for pain management” towards ameliorating pain, including chronic pain such as fibromyalgia, with its SP-26 program using a...

Biotech company Psycheceutical Bioscience Inc. (OTC: BWVI) has published observational data supporting the potential of its proprietary ketamine topical cream NeuroDirect for the treatment of PTSD.  Observational data were collected in a non-clinical setting from an outpa­tient...

Irwin Naturals Inc. (OTC: IWINF) has terminated the non-binding amended and restated letter of intent (LOI) for a business combination with medical research and telemedicine company Braxia Scientific Corp. (OTC PINK: BRAXF). CEO Klee Irwin said the decision was based on a “lack of a clear...

Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.   This is the first time Awakn, a psychedelics biotech and services provider, will license its protocols...

Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.  The exclusive agreement is set to design and conduct two Phase...

Awakn Opens Fourth European Clinic, Norway Takes Center Stage Awakn Life Sciences Corp. (OTCQB: AWKNF), a psychedelics biotech company with a near-term focus on Alcohol Use Disorder (AUD), has opened a new clinic providing its proprietary ketamine-assisted psychotherapy (KAP) in the center of...

Clinical-stage biopharma psychedelics company Seelos Therapeutics Inc. (NASDAQ: SEEL) announced it has dosed the first patients in a Phase 1 study with healthy adult Japanese and non-Asian participants to compare the safety and pharmacokinetic (PK) profiles of proprietary intranasal racemic...

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. FDA’s Orphan Drug Status To Ketamine For Rett Syndrome The FDA granted an orphan drug designation to the company’s proprietary...

Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained positive results from the latest preclinical trial on a next-gen psychedelic for the treatment...

After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with a clinical trial assessing low-dose, weekly intravenous (IV) ketamine infusion in participants with Major Depressive...

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation. Orphan drug designation, which grants special status to a sponsor’s drug or biological product to...

While psychedelics are still listed as Schedule I substances making them illegal under federal law, companies across North America are preparing to address patients’ needs in the hopefully upcoming psychedelics-assisted therapies (PAT) scenario. Ketamine Treatment Center Opens...

Psychedelics-assisted therapy provider Field Trip Health & Wellness Ltd. has launched Freedom by Field Trip, a novel and unmatched one-year hybrid program combining ketamine-assisted therapy (KAP) with holistic wellness support. Initially available in California and Washington state, non-...